Scientific Information

WELCOME

Yves Ville, France

Priorities for current research: Results of a European survey

Pamela Vallely, United Kingdom

Patients’ voice. Their priorities:

Anne Hélène Labissy, France

Discussion

BREAK AND POSTER VIEW

EPIDEMIOLOGY IN EUROPE

Chairs: Suzanne Smit, Belgium; Marianne Leruez, France

Overview

Suzanne Smit, Belgium

The high risk group

Marianne Leruez, France

Congenital CMV infection following maternal infection in the second and third trimester of pregnancy is associated with mild sequelae not predicted by prenatal imaging

Shlomo Lipitz, Israel

Survey of congenital cytomegalovirus in France : focus to fetal and newborn symptomatology in 2018 and 2019

Elodie Ribot, France

Antibody features and functions distinguish primary from latent CMV infection during pregnancy

Andrew Hederman, United States

Congenital cytomegalovirus awareness among pregnant women in a tertiary hospital in Barcelona, and knowledge of the infection among prenatal health care providers in Catalunya (Spain): an action towards prevention

Anna Gonce, Spain

Evolution of awarness and knowledge of congenital cytomegalovirus infection among health care providers in France between 2001 and 2018

Christelle Vauloup Fellous, France

Discussion

PREVENTION

Chairs: Chrissie Jones, United Kingdom; Arnauld Marchant, Belgium

PRIMARY PREVENTION

Overview

Chrissie JONES (UK)

SECONDARY PREVENTION

Debate:

HIIG work : the MFMN randomized trial of cytogam to prevent congenital cytomegalovirus infection was flawed Stuart Adler, United States HIIG do not work : Daniele Lilleri, Italy

How to optimize passive immunization for prevention of maternofetal CMV transmission: impact of virological inclusion criteria

Karl Oliver Kagan, Germany

Val-acyclovir to Prevent congenital CMV After Maternal Primary Infection early in Pregnancy

Jacob Amir, Israel

Fibroblast infection by cytomegalovirus has evolved a mechanism to escape neutralizing antibodies

Michael Mcvoy, United States

Trimeric artesunate TF27 shows strong anti-cytomegalovirus efficacy by oral administration in vivo and favorable drug interactions in vitro

Markus Wild, Germany

Treatment of women with a primary CMV infection in pregnancy with high-dose CMV hyperimmune globulin (cytotect) does not cause placental syndrome.

Stuart Adler, United States

Discussion

BREAK AND POSTER VIEW

TERTIARY PREVENTION (Fetal and Neonatal treatment)

Antiviral treatment in pregnancy

Marianne Leruez, France

Neonatal treatment (overview)

Ann Vossen, the Netherlands

Antiviral targeting strategies based on pharmacological inhibitors directed to the human cytomegalovirus-encoded protein kinase pUL97

Manfred Marschall, Germany

Impact of letermovir in an ex vivo first-trimester placenta model.

Elodie Ribot, France

Discussion

DIAGNOSTIC OF MATERNAL INFECTION

Chairs : Ann Vossen, the Netherlands; Tiziana Lazzarotto, Italy

Welcome to Day 2

Overview primary infection

Tiziana Lazzarotto, Italy

Overview Non-primary infection

Daniele Lilleri, Italy

Discussion

BREAK AND POSTER VIEW

DIAGNOSTIC OF FETAL INFECTION

Chairs : Catherine Donner, Belgium; Anna Gonce, Sweden

Overview

Yves Ville, France

Antibody response to primary cytomegalovirus infection during pregnancy

Shilpee Sharma, Belgium

Does T-cell mediated immune response to cytomegalovirus infection play a role in preventing intrauterine transmission? (cytric study)

María Soriano-Ramos, Spain

Cortical maturation assessed by magnetic resonance imaging in unaffected/mildly affected fetuses with cytomegalovirus infection.

Ameth Hawkins-Villarreal, Spain

RNA sequencing of amniotic fluid reveals activation of the innate immune response and differential expression of neurodevelopmental transcripts in midtrimester human fetuses with cytomegalovirus infection

Lisa Hui, Australia

Serial ultrasound assessment for identifying fetuses at risk of postnatal sequelae from cytomegalovirus infection: an Italian multicenter retrospective study

Sara Ornaghi, Italy

The performance of amniocentesis for the diagnosis of congenital cytomegalovirus infection at 17 weeks of amenorrhea is just as strong as when performed one month later

Valentine Faure Bardon, France

Discussion

VACCINE quo vadis

Overview

Arnauld Marchant, Belgium

A Messenger RNA (mRNA) Vaccine Against Cytomegalovirus (CMV) Infection: Phase 2 Interim Data

Lori Panther, United States

Discussion

BREAK AND POSTER VIEW

PEDIATRICS - PART 1

Chairs : Daniel Blazquez-Gamero, Spain; Ina Foulon, Belgium

Management of SNHL

Ina Foulon, Belgium

Implants: technique and outcome

Natacha Tessier, France

Eagle score. A multicentric cohort study about hearing loss in congenital cytomegalovirus infection.

Serena Villaverde, Spain

Cochleovestibular involvement in human fetuses with congenital CMV infection

Liliana Gabrielli, Italy

Discussion

BREAK AND POSTER VIEW

PEDIATRICS – PART II

ChaiChairs: Daniel Blazquez-Gamero, Spain, Ina Foulon, Belgium

Pediatric burden of non-primary infections

Vanna Papaevangelou, Greece

Kinetics of salivary and blood viral loads in a cohort of children with congenital CMV infection

Jacques Fourgeaud, France

Cranial ultrasound and MRI : do both matter in the diagnostic work-up of children with congenital CMV?

Annelies Keymeulen, Belgium

Evaluation of the SIMPLEXA™ congenital CMV direct assay for newborn cytomegalovirus testing using saliva and urine samples

Tiziana Lazzarotto, Italy

Discussion and closing remarks